Mumtarin Jannat Oishee

Mumtarin Jannat Oishee

Auto-generated profile, based on publicly available information

Mumtarin Jannat Oishee

Department of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
MOMumtarin Jannat Oishee
Mumtarin Jannat Oishee
TATamanna Ali
Tamanna Ali
NJNowshin Jahan
Nowshin Jahan
Shahad Saif KhandkerShahad Saif Khandker
Shahad Saif Khandker
MHMd. Ahsanul Haq
Md. Ahsanul Haq
NANihad Adnan
Nihad Adnan
Recent severe acute respiratory syndrome 2 (SARS-CoV-2) known as COVID-19, presents a deadly challenge to the global healthcare system of developing and developed countries, exposing the limitations of health facilities preparedness for emerging infectious disease pandemic. Opportune detection, confinement, and early treatment of infected cases present the first step in combating COVID-19. In this review, we elaborate on various COVID-19 diagnostic tools that are available or under investigation. Consequently, cell culture, followed by an indirect fluorescent antibody, is one of the most accurate methods for detecting SARS-CoV-2 infection. However, restrictions imposed by the regulatory authorities prevented its general use and implementation. Diagnosis via radiologic imaging and reverse transcriptase PCR assay is frequently employed, considered as standard procedures, whereas isothermal amplification methods are currently on the verge of clinical introduction. Notably, techniques such as CRISPR-Cas and microfluidics have added new dimensions to the SARS-CoV-2 diagnosis. Furthermore, commonly used immunoassays such as enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay (LFIA), neutralization assay, and the chemiluminescent assay can also be used for early detection and surveillance of SARS-CoV-2 infection. Finally, advancement in the next generation sequencing (NGS) and metagenomic analysis are smoothing the viral detection further in this global challenge.

1 July 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
BSBijon Kumar Sil
Bijon Kumar Sil
MJMohd Raeed Jamiruddin
Mohd Raeed Jamiruddin
MHMd. Ahsanul Haq
Md. Ahsanul Haq
MKMohib Ullah Khondoker
Mohib Ullah Khondoker
NJNowshin Jahan
Nowshin Jahan
NANihad Adnan
Nihad Adnan
Background: Serological tests detecting severe acute respiratory syndrome coronavirus− 2 (SARS-CoV-2) are widely used in seroprevalence studies and evaluating the efficacy of the vaccination program. Some of the widely used serological testing techniques are enzyme-linked immune-sorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and lateral flow immunoassay (LFIA). However, these tests are plagued with low sensitivity or specificity, time-consuming, labor-intensive, and expensive. We developed a serological test implementing flow-through dot-blot assay (FT-DBA) for SARS-CoV-2 specific IgG detection, which provides enhanced sensitivity and specificity while being quick to perform and easy to use. Methods: SARS-CoV-2 antigens were immobilized on nitrocellulose membrane to capture human IgG, which was then detected with anti-human IgG conjugated gold nanoparticle (hIgG-AuNP). A total of 181 samples were analyzed in-house. Within which 35 were further evaluated in US FDA-approved CLIA Elecsys SARS-CoV-2 assay. The positive panel consisted of RT-qPCR positive samples from patients with both < 14 days and > 14 days from the onset of clinical symptoms. The negative panel contained samples collected from the pre-pandemic era dengue patients and healthy donors during the pandemic. Moreover, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FT-DBA were evaluated against RT-qPCR positive sera. However, the overall efficacies were assessed with sera that seroconverted against either nucleocapsid (NCP) or receptor-binding domain (RBD). Results: In-house ELISA selected a total of 81 true seropositive and 100 seronegative samples. The sensitivity of samples with < 14 days using FT-DBA was 94.7%, increasing to 100% for samples > 14 days. The overall detection sensitivity and specificity were 98.8% and 98%, respectively, whereas the overall PPV and NPV were 99.6% and 99%. Moreover, comparative analysis between in-house ELISA assays and FT-DBA revealed clinical agreement of Cohen’s Kappa value of 0.944. The FT-DBA showed sensitivity and specificity of 100% when compared with commercial CLIA kits. Conclusion: The assay can confirm past SARS-CoV-2 infection with high accuracy within 2 minutes compared to commercial CLIA or in-house ELISA. It can help track SARS-CoV-2 disease progression, population screening, and vaccination response. The ease of use of the assay without requiring any instruments while being semi-quantitative provides the avenue of its implementation in remote areas around the globe, where conventional serodiagnosis is not feasible.

1 June 2021 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
MJMohd Raeed Jamiruddin
Mohd Raeed Jamiruddin
MHMd. Ahsanul Haq
Md. Ahsanul Haq
KTKazuhito Tomizawa
Kazuhito Tomizawa
EKEiry Kobatake
Eiry Kobatake
MMMasayasu Mie
Masayasu Mie
NANihad Adnan
Nihad Adnan
Background: Dynamics and persistence of neutralizing and non-neutralizing antibodies can give us the knowledge required for serodiagnosis, disease management, and successful vaccine design and development. The disappearance of antibodies, absence of humoral immunity activation, and sporadic reinfection cases emphasize the importance of longitudinal antibody dynamics against variable structural antigens. Methods: In this study, twenty-five healthy subjects working in a SARS-COV-2 serodiagnostic assay development project were enrolled, and their sign and symptoms were followed up to six months. Three subjects showed COVID-19-like symptoms, and three subjects’ antibody dynamics were followed over 120 days by analyzing 516 samples. We have developed 12 different types of in-house ELISAs to observe the kinetics of IgG, IgM, and IgA against four SARS-CoV-2 proteins, namely nucleocapsid, RBD, S1, and whole spike (S1+S2). For the development of these assays, 30– 104 pre-pandemic samples were taken as negative controls and 83 RT-qPCR positive samples as positive ones. Results: All three subjects presented COVID-19-like symptoms twice, with mild symptoms in the first episode were severe in the second, and RT-qPCR confirmed the latter. The initial episode did not culminate with any significant antibody development, while a multifold increase in IgG antibodies characterized the second episode. Interestingly, IgG antibody development concurrent with IgM and IgA and persisted, whereas the latter two weans off rather quickly if appeared. Conclusion: Antibody kinetics observed in this study can provide a pathway to the successful development of sero-diagnostics and epidemiologists to predict the fate of vaccination currently in place.

16 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MOMumtarin J Oishee
Mumtarin J Oishee
JMJeff McDermott
Jeff McDermott
GSGladis Sánchez
Gladis Sánchez
GBGustavo Blanco
Gustavo Blanco
Na + ,K + -ATPase α4 is a unique cell plasma membrane Na + and K + transporter of spermatozoa, which is essential for male fertility. Previous studies have shown that Na + ,K + -ATPase α4 is highly expressed in the sperm flagellum; however, the spatial arrangement of Na + ,K + -ATPase α4 at the subcellular level and its relationship to the functional state of the cells are unknown. We studied this here using stimulated emission depletion (STED) super-resolution microscopy. We show that, under non-capacitated conditions, Na + ,K + -ATPase α4 is distributed in a trilinear pattern along the midpiece and as a scattered single line along the principal piece segment of the sperm flagellum. Under capacitated conditions, Na + ,K + -ATPase α4 pattern undergoes remodelling and its distribution shifts into a single line along the entire length of the flagellum. On the other hand, Na + ,K + -ATPase α1 the somatic isoform of Na + ,K + -ATPase also present in sperm, exhibits a similar trilaminar localization at the flagellar midpiece but a bilinear pattern in the principal piece. This distribution, unlike that of Na + ,K + -ATPase α4, does not change during sperm capacitation. These differences in the localization pattern and spatial dynamics of Na + ,K + - ATPase isoform expression highlights the dissimilarities in the roles of both ion transporters. The specific modulation of Na + ,K + -ATPase α4 distribution, combined with the unique role that it has in sperm function, stresses the importance of Na + ,K + -ATPase α4 for male fertility. Significance statement: This is the first demonstration of the highly structured nature of Na + ,K + -ATPase in the plasma membrane of sperm, including the sperm specific Na + ,K + -ATPase α4 isoform, which is key for male fertility, and the somatic Na + ,K + -ATPase α1, which is present in all cells. Utilizing stimulated emission depletion (STED) super resolution microscopy, we discovered that Na + ,K + - ATPase α4 and Na + ,K + -ATPase α1 have different distributions along the sperm flagellum. Moreover, only Na + ,K + -ATPase α4 undergoes remodelling during sperm capacitation. These specific patterns of localization that are dependent on the sperm functional state in combination with the different function and regulation of Na + ,K + -ATPase isoforms highlights the sophisticated mechanisms that cells have evolved to fulfil their unique function.

11 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BSBijon Kumar Sil
Bijon Kumar Sil
MOMumtarin Jannat Oishee
Mumtarin Jannat Oishee
MHMd. Ahsanul Haq
Md. Ahsanul Haq
NJNowshin Jahan
Nowshin Jahan
TATamanna Ali
Tamanna Ali
NANihad Adnan
Nihad Adnan
Background: In the ongoing pandemic situation of COVID-19, serological tests can complement the molecular diagnostic methods, and can be one of the important tools of sero-surveillance and vaccine evaluation. Aim: To develop and evaluate a rapid SARS-CoV-2 specific ELISA for detection of anti-SARS-CoV2 IgG from patient’s biological samples. Methods: In order to develop the ELISA, three panels of samples (n=184) have been used: panel 1 (n=19) and panel 2 (n=60) were collected from RT-PCR positive patients within 14 and after 14 days of onset of clinical symptoms respectively, whereas panel 3 consisted of negative samples (n=105) collected either from healthy donors or pre-pandemic dengue patients. As a capturing agent full-length SARS-CoV2 specific recombinant nucleocapsid was immobilized. Commercial SARS-CoV2 IgG kit based on chemiluminescent assay was used for the selection of samples and optimization of the assay. The threshold cut-off point, inter-assay and intra-assay variations were determined. The total assay time for this in-house ELISA was set for 30 minutes. Results: The assay time was set at a total of 30 minutes with the sensitivity of 84% (95% confidence interval, CI, 60.4%, 96.6%) and 98% (95% CI, 91.1%, 100.0%), for panel 1 and 2 respectively, with over all 94.9% sensitivity (95% CI 87.5%, 98.6%). Moreover, the clinical specificity is 97.1% (95% CI, 91.9%, 99.4%) with no cross reaction with dengue sample. The overall positive and negative predictive values are 96.2% (95% CI 89.2%, 99.2%) and 96.2% (95% CI, 90.6% 99.0%) respectively. In-house ELISA demonstrated 100% positive and negative percent agreement with ROCHE (Elecsys; Anti-SARS-CoV-2), with a Cohen’s kappa value of 1.00 (very strong agreement), while comparing 13 positive and 17 negative confirmed cases. Conclusion: The assay is rapid and can be applied as one of the early and retrospective sero-monitoring tools in all over the affected areas.

22 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BSBijon Kumar Sil
Bijon Kumar Sil
NANihad Adnan
Nihad Adnan
MOMumtarin Jannat Oishee
Mumtarin Jannat Oishee
TATamanna Ali
Tamanna Ali
NJNowshin Jahan
Nowshin Jahan
MJMohd Raeed Jamiruddin
Mohd Raeed Jamiruddin
COVID-19 pandemic situation demands effective serological tests with a view to adopting and developing policy for disease management, determining protective immunity as well as for sero-epidemiological study. Our study aims to develop and evaluate two rapid in-house ELISA assays targeting neutralizing antibodies (IgG) against S1 subunit of spike in SARS-CoV-2 and Receptor Binding Domain (RBD), as well as comparative analysis with nucleocapsid (NCP) ELISA. The assays were conducted with 184 samples in three panels collected from 134 patients. Panel 1 and 2 consist of RT-PCR positive samples collected within two weeks and after two weeks of symptom onset, respectively. Negative samples are included in panel 3 from healthy donors and pre-pandemic dengue patients. The total assay time has been set 30 minutes for both of the ELISA assays. Results show that S1 and RBD ELISA demonstrates 73.68% and 84.21% sensitivities, respectively for samples collected within two weeks, whereas 100% sensitivities were achieved by both for samples that were collected after two weeks of the onset of symptoms. S1-ELISA shows 0% positivity to panel 3 while for RBD-ELISA the figure is 1%. A strong correlation (r s =0.804, p<0.0001)) has been observed between these two assays. When compared with NCP-ELISA, S1 slightly better correlation (r s =0.800, p<0.0001) than RBD (r s =0.740, p<0.0001). Our study suggests S1-ELISA as more sensitive one than the RBD or nucleocapsid ELISA during the later phase of infection, while for overall sero-monitoring RBD specific IgG ELISA is recommended. Moreover, non-reactivity to dengue emphasize the use of these assays for serosurveillance of COVID-19 in the dengue endemic regions. Highlights: The total assay time of these assays are 30 minutes. Sensitivity of S1 specific IgG ELISA for samples tested within 14 days of disease presentation is 73.68% while RBD specific ELISA demonstrates a sensitivity of 84.21%, Both of the assays under investigation can successfully detect all the cases (100% sensitivity) if the samples are tested after 14 days of onset of diseases. Specificity of S1-ELISA assay is 100%, whereas RBD specific IgG ELISA is 99% specific. The assays can be employed in dengue-endemic countries Among the three in-house IgG ELISA, assay system specific to S1 is found to be more sensitive and specific for retrospective serosurveillance. For acute to late phase, as well as retrospective serosurveillance of COVID-19, RBD-ELISA can be a method of choice for SARS-CoV-2 prevalent areas.